Jupiter Neurosciences Inc. Common Stock (JUNS)
Stock · NASDAQ · Health Care
$2.9as of 10/16/2026
Price chart
Active signals
JUNS Signal Track Record
How signals performed across all stocks →What JUNS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 10 | -15.5% | 20% | October 6, 2026 |
| Bollinger Band Breakdown | 6 | -15.2% | 17% | September 28, 2026 |
| Bollinger Band Breakout | 4 | -29.5% | 0% | August 7, 2026 |
| Any 20-session window (baseline) | -19.8% | 9% |
Computed by MarketWall from daily closing prices since September 22, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About JUNS
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the trea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 5
- Website
- jupiterneurosciences.com/
Fundamentals
- 1-day range
- $3$3.44
- Market cap
- $4.24M
- P/E (trailing)
- —
- P/E (forward)
- 55.42
- EPS (trailing)
- $-18.57
- Dividend yield
- —
- Beta
- 0.57
- Avg. volume
- 983.5K
How Jupiter Neurosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Apr 1, 2026 · via SEC EDGAR / Finnhub
Jupiter Neurosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- JUNSJupiter Neurosciences Inc. Common Stock$2.9▼ 7.48%Market cap $4.24MP/E —$2.25$135.75
- ELABPMGC Holdings Inc. Common Stock$2.77▼ 8.88%Market cap $4.34MP/E —$2.59$2,671
- REVBRevelation Biosciences Inc. Common Stock$0.485▼ 36.35%Market cap $4.38MP/E 0.04$0.71$5.8
- DRMADermata Therapeutics Inc. Common Stock$0.86▼ 5.49%Market cap $4.46MP/E —$0.6032$4.66
- INMInMed Pharmaceuticals Inc. Common Shares$1.32▼ 0.75%Market cap $4.01MP/E —$0.575$2.33
- RNAZTransCode Therapeutics Inc. Common Stock$1.7▼ 5.56%Market cap $4.52MP/E —$1.52$15.94
- JAGXJaguar Health Inc. Common Stock$3.53▼ 23.20%Market cap $4.61MP/E —$2.35$1,268
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| JUNS Jupiter Neurosciences Inc. Common Stock | $4.24M | — | $2.9 | ▼ 7.48% | $2.25$135.75 |
| ELAB PMGC Holdings Inc. Common Stock | $4.34M | — | $2.77 | ▼ 8.88% | $2.59$2,671 |
| REVB Revelation Biosciences Inc. Common Stock | $4.38M | 0.04 | $0.485 | ▼ 36.35% | $0.71$5.8 |
| DRMA Dermata Therapeutics Inc. Common Stock | $4.46M | — | $0.86 | ▼ 5.49% | $0.6032$4.66 |
| INM InMed Pharmaceuticals Inc. Common Shares | $4.01M | — | $1.32 | ▼ 0.75% | $0.575$2.33 |
| RNAZ TransCode Therapeutics Inc. Common Stock | $4.52M | — | $1.7 | ▼ 5.56% | $1.52$15.94 |
| JAGX Jaguar Health Inc. Common Stock | $4.61M | — | $3.53 | ▼ 23.20% | $2.35$1,268 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · 9/24/2026
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · 9/22/2026
Insider Activity
Insider Actions →- Cutler Andrew Jon · July 31, 2026 · Grant472.2K
- Philipson Tomas Jan · June 29, 2026 · Grant536.4K
- Brady Allison W · June 2, 2026 · Grant100.0K
- ROSEN CHRISTER · June 2, 2026 · Grant747.8K
- Hemmerly Nicholas H. · June 2, 2026 · Grant100.0K
- Kampf Julie B. · June 2, 2026 · Grant100.0K
- Silva Alison D. · June 2, 2026 · Grant1.03M
- Hayward Marshall A. · June 2, 2026 · Grant259.2K
- Holger Weis · June 2, 2026 · Grant100.0K
- Rosen Alexander Gustaf Erik · June 2, 2026 · Grant341.8K
- Elmasri Saleem · June 2, 2026 · Grant525.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
JUNS doses first patient in Phase 2a Parkinson’s trial
Jupiter Neurosciences reported that the first participant has been dosed in its Phase 2a RESET trial of JOTROL for Parkinson’s disease. The company also said it is reviewing strategic options to enhance shareholder value. The trial start follows recent mixed movement in healthcare stocks, but the dosing event provides a specific catalyst for the company.
JUNS doses first patient in Phase 2a Parkinson’s trial. Jupiter Neurosciences reported that the first participant has been dosed in its Phase 2a RESET trial of JOTROL for Parkinson’s disease. The company also said it is reviewing strategic options to enhance shareholder value. The trial start follows recent mixed movement in healthcare stocks, but the dosing event provides a specific catalyst for the company.